References

Back to Formulary page

1. Centers for Disease Control and Prevention.  IND Protocol:  Use of NP-018 Heptavalent Equine-Based Botulinum Antitoxin (H-BAT) After Exposure to Clostridium botulinum Toxin or Other Closely-Related Botulinum Toxin-Producing Clostridia Species Due to a Naturally-Occurring Outbreak or Isolated Incident.  BB-IND 6750, December 11, 2009: version 6.
2. Centers for Disease Control and Prevention.  Investigational Heptavalent Botulinum Antitoxin (HBAT) to Replace Licensed Botulinum Antitoxin AB and Investigational Botulinum Antitoxin E.  MMWR, March 19, 2010 59(10); 299.
3. Centers for Disease Control and Prevention: Botulism in the United States, 1899-1996. Handbook for Epidemiologists, Clinicians, and Laboratory Workers, Atlanta, GA. Centers for Disease Control and Prevention, 1998.
4. Grabenstein JD.  ImmunoFacts:  Vaccines & Immunologic Drugs.  St, Louis, MO:  Wolters Kluwer Health, Inc; 2004 (269, 342, 1019).
5. Centers for Disease Control and Prevention: Availability of diphtheria antitoxin through an investigational new drug protocol. MMWR, May 21, 2004; 53(19):  413.
6. Centers for Disease Control and Prevention. Smallpox Vaccination and Adverse Events:  Guidance for Clinicians. MMWR, February 21, 2003; 52(RR04);1-28.
7. Centers for Disease Control and Prevention.  IND Protocol:  Use of Pentavalent (ABCDE) Botulinum Toxoid Aluminum Phosphate Adsorbed (PBT) for Workers at Risk of Occupational Exposure to Botulinum Toxoins.  BB-IND 161, March 27, 2006: version 6.
8. Centers for Disease Control and Prevention.  Notice to Readers:  Newly Licensed Smallpox Vaccine to Replace Old Smallpox Vaccine.  MMWR, February 29, 2008 57(8); 207-208.
9. Centers for Disease Control and Prevention. Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, June 22, 2001 / 50(RR10);1-25.
10. Centers for Disease Control and Prevention. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, December 15, 2000; 49(RR15);1-20.
11. Centers for Disease Control and Prevention.  Intravenous Artesunate for Treatment of Severe Malaria in the United States.  IND Protocol #76,725; July, 2007: 1-48.
12. Addis DG, Dreyer G. Treatment of lymphatic filariasis. In: Nutman, TB, ed. Chapter 7:  Treatment of Lymphatic Filariasis (Tropical Medicine: Science and Practice). London: Imperial College Press; 2000: 151-199.
13. Centers for Disease Control and Prevention.  Diethylcarbamazine (DEC) for the treatment of filariasis.  IND Protocol #57,944; 2006:  1-33.
14. Centers for Disease Control and Prevention. Melarsoprol IND Protocol #84,457; 1996:1-14.
15. Centers for Disease Control and Prevention. Nifurtimox IND Protocol #84,422; 1987:1-11.
16. Centers for Disease Control and Prevention. Pentostam IND Protocol #84,831; 1995:1-20.
17. Herwaldt, B, Berman, J.  “Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies” Am J of Med Hyg; 46(3), 1992: 296–306.
18. Centers for Disease Control and Prevention. Suramin IND Protocol #84,459; September, 1997:  1-11.